The First Affiliated Hospital of Zhejiang University School of Medicine successfully held the clinical launch meeting to include moderate to severe active systemic lupus erythematosus (SLE) into the investigator-initiated clinical trial (IIT) for the metabolically armed CD19 CAR-T cells (Meta10-19 Injection).
